1 Cell-free DNA Fragmentomics Assay to Discriminate the Malignancy of Breast

2 Nodules and Evaluate Treatment Response

- 3 Jiaqi Liu^{1,2,3,#}, Yalun Li^{4,#}, Wanxiangfu Tang^{5,#}, Lijun Dai^{2,#}, Ziqi Jia^{3,#}, Heng Cao³, Chenghao Li²,
- 4 Yuchen Liu^{3,6}, Yansong Huang^{3,6}, Jiang Wu³, Dongxu Ma³, Guangdong Qiao⁴, Hua Bao⁵, Shuang
- 5 Chang⁵, Dongqin Zhu⁵, Shanshan Yang⁵, Xuxiaochen Wu⁵, Xue Wu⁵, Hengyi Xu^{1,6}, Hongyan Chen¹,
- 6 Yang Shao⁵, Xiang Wang^{3,*}, Zhihua Liu^{1,*}, Jianzhong Su^{2,*}
- ⁷ ¹State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research
- 8 Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union
- 9 Medical College, Beijing 100021, China
- ²Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), Eye
 Hospital, Wenzhou Medical University, Wenzhou 325027, China
- 12 ³Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research
- 13 Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union
- 14 Medical College, Beijing 100021, China
- ⁴Department of Breast Surgery, the Affiliated Yantai Yuhuangding Hospital of Qingdao University,
 Yantai 264000, China
- ¹⁷ ⁵Nanjing Geneseeq Technology Inc., Nanjing 210061, China
- ¹⁸ ⁶School of Clinical Medicine, Chinese Academy of Medical Sciences and Peking Union Medical
- 19 College, Beijing 100005, China
- 20 [#]These authors contributed equally to this article.
- 21 *Corresponding authors.
- 22 E-mail: <u>sujz@wmu.edu.cn (Su J); liuzh@cicams.ac.cn (Liu Z); xiangw@vip.sina.com (Wang X)</u>.
- 23
- 24 Running Title: Liu J et al. / Detecting Breast Cancer Through cfDNA Fragmentomics
- 25
- 26

27 Abstract

The fragmentomics-based cell-free DNA (cfDNA) assays have recently illustrated prominent abilities 28 to identify various cancers from non-conditional healthy controls, while their accuracy for identifying 29 early-stage cancers from benign lesions with inconclusive imaging results remains uncertain. 30 Especially for breast cancer, current imaging-based screening methods suffer from high false-positive 31 rates for women with breast nodules, leading to unnecessary biopsies, which add to discomfort and 32 healthcare burden. Here, we enroll 560 female participants in this multi-center study and demonstrate 33 that cfDNA fragmentomics is a robust non-invasive biomarker for breast cancer using whole-genome 34 sequencing. Among the multimodal cfDNA fragmentomics profiles, the fragment size ratio (FSR), 35 fragment size distribution (FSD), and copy number variation (CNV) show more distinguishing ability 36 than Griffin, motif breakpoint (MBP), and neomer. The cfDNA fragmentomics (cfFrag) model using 37 38 the optimal three fragmentomics features discriminated early-stage breast cancers from benign nodules, even at a low sequencing depth $(3\times)$. Notably, it demonstrated a specificity of 94.1% in 39 asymptomatic healthy women at a 90% sensitivity for breast cancers. Moreover, we comprehensively 40 showcase the clinical utilities of the cfFrag model in predicting patient responses to neoadjuvant 41 42 chemotherapy (NAC) and in combining with multimodal features, including radiological results and cfDNA methylation features (with AUC values of 0.93 - 0.94 and 0.96, respectively). 43

44

Keywords: Cell-free DNA methylation; Fragmentomics; Breast cancer; Whole-genome sequencing;
 Neoadjuvant chemotherapy

47

48

49 Introduction

Breast cancer is one of the most common types of cancer worldwide and accounts for the highest 50 number of cancer-related deaths among females [1]. Early detection of breast cancer is crucial for 51 improving patients' outcomes and survival [2]. However, current imaging-based screening 52 methodologies, including mammography and ultrasonography, suffer from high false-positive rates, 53 leading to many unnecessary biopsies, adding to patient discomfort [3]. Meanwhile, tumor 54 biomarkers such as CA15-3 lack sensitivity for early-stage breast cancer [4]. Thus, liquid biopsies are 55 56 needed as a non-invasive alternative or adjunct to select the high breast cancer-risk women for tumor biopsies [5]. 57

Mutation-based circulating tumor DNA (ctDNA) detection has become the companion diagnostic 58 by identifying actionable targets and alterations mediating resistance (e.g., ESR1 and PIK3CA 59 60 mutations in breast cancer) [6-8]. However, ctDNA typically lacks mutations, especially in early-stage disease, which limits its application in these contexts and reduces its ability to anticipate 61 62 the diagnosis of localized cancer [9]. Besides, lacking common mutations in breast cancer limits the detection sensitivity in the patient-naïve approach [10]. Epigenetic analysis approaches offer potential 63 solutions to fully exploit liquid biopsy in various settings [11, 12]. We previously conducted a 64 whole-genome DNA methylation analysis on cell-free DNA (cfDNA) and identified ten optimal DNA 65 methylation markers associated with breast cancer, which could enhance early detection [4]. However, 66 current bisulfite-based methylation sequencing is prone to cfDNA damage, resulting in high cfDNA 67 68 amount, depth dependencies, and increased cost.

Fragmentomics-based cfDNA assays have recently illustrated prominent abilities to identify various cancer types from paired non-conditional healthy controls using whole-genome sequencing (WGS) [13-17] and targeted cfDNA panels [18]. Similar to most cancer types, benign tumors also release ctDNA with unique features [19]. However, the accuracies of the cfDNA fragmentomics profile for identifying early-stage cancers from benign lesions with similar symptoms or inconclusive imaging results and predicting the therapeutic response remain largely unclear.

Herein, we developed a non-invasive liquid biopsy assay for early-stage breast cancer diagnosis which analyzes cfDNA fragmentomics through low-depth WGS and machine learning (**Figure 1**). To reveal its clinical utilities, we comprehensively evaluated the performances of this cfDNA fragmentomics assay in diagnosing early-stage breast cancer from benign breast nodules, predicting patient responses to neoadjuvant chemotherapy (NAC), and combining with multimodal features,

including standard imaging techniques and cfDNA methylation markers. This approach is particularly beneficial for female patients who have undergone unnecessary biopsies due to false positives from imaging tests on benign breast nodules. Additionally, it can offer valuable insights into neoadjuvant treatment planning for breast cancer patients. Combining a cfDNA fragmentomics assay with standard imaging techniques enhances the early detection rate of breast cancer, potentially improving breast cancer survival rates.

86 **Results**

87 Patient characteristics in two independent cohorts

We enrolled a total of 560 female participants in this multi-center study. In the training set, we 88 89 enrolled 91 patients with breast cancers and 102 women with breast benign nodules from the Affiliated Yantai Yuhuangding Hospital of Qingdao University (YYH) in Yantai, China. Seven 90 91 patients who refused to biopsy were excluded. In the external validation cohort, we recruited 143 patients with breast cancers and 66 women with benign nodules from the Cancer Hospital of the 92 Chinese Academy of Medical Sciences (CHCAMS) in Beijing, China. The external screening cohort 93 recruited 119 asymptomatic healthy women from our previous cohort of non-cancer healthy 94 95 volunteers in Nanjing, China (Nanjing Cohort [14]). NAC validation cohort included 9/33 (27.3%) patients with pathological complete response (pCR) and 24/33 (72.7%) patients with non-pCR from 96 the CHCAMS. The robustness analysis cohort contained three stage-II breast cancer patients and 97 three patients with benign nodules (Figure 2). 98

The breast cancer patients enrolled in the training and validation cohorts were all in the early stages (0-II), including 8.8% and 16.0% in ductal carcinoma *in situ* (DCIS)/stage 0, 36.3% and 39.9% in stage I, 54.9% and 42.0% in stage II (Table S1). Among these patients, the majority type of breast cancer (80.4% - 85.7%) was invasive ductal carcinoma (IDC), and 16.1% - 18.7% of them were identified as triple-negative breast cancer (TNBC) in both cohorts.

104 Whole-genome multi-features analysis of cell-free DNA identifies the optimizing cfDNA 105 fragmentomics profiles for breast cancer detection

In the Yantai cohort (training set), an average amount of 5.6 ng cfDNA (2.3 - 26.5 ng) was extracted from 500ul plasma. In the Beijing cohorts (validation set), 2 ml plasma was used to extract cfDNA for an average amount of 8.8 ng (3.4 - 13.5 ng). We applied low-depth WGS to the cfDNA samples. Libraries were sequenced in 7.4× mean depth (2.9 - 11.3×) in the training set and 8.8× mean

110 depth $(3.4 - 13.5 \times)$ in the validation set, resulting in a highly unique mapping rate and unique deduplicated mapping rate of more than 99.96%. The fragmentomics profiles were generated using 111 112 low-depth WGS data from plasma cfDNA. To find optimal features for model construction, six types of fragmentomics profiles, including copy number variation (CNV), fragment size distribution (FSD), 113 fragment size ratio (FSR), Griffin, motif breakpoint (MBP), and neomer, were generated using 114 in-house scripts as previously reported [13, 15, 20-23]. Distinct spectrums of cfDNA fragmentomics 115 features were found in patients with breast cancers and benign nodules, especially in CNV, FSD, and 116 FSR (Figure S1). 117

We used the ichorCNA [15] reported tumor fraction (TF) to show the differences in CNV profile between breast cancer patients and benign nodule patients. As shown in Figure S2, the ichorCNA reported TF was significantly higher for the breast cancer patients than the benign nodule patients in both the training cohort ($P = 8.0 \times 10^{-5}$) and the validation cohort (P = 0.029). This suggests that while the breast cancer and benign groups both vary substantially from health baselines, there are still distinguishable differences between the two groups.

Next, base learners were constructed and optimized utilizing the machine-learning process utilizing five different algorithms of the machine-learning process [13] on the training set (Figure 1). Among the six fragmentomics features, CNV, FSD, and FSR demonstrated significantly higher area under the curve (AUC) values compared to all features (student's *t*-test, $P = 1.1 \times 10^{-3}$, 4.3×10^{-3} , and 2.7×10^{-2} , respectively; **Figure 3**A).

129 The cfDNA fragmentomics (cfFrag) model accurately distinguishes early-stage breast cancers 130 from benign nodules with high specificity in asymptomatic healthy women

131 The cfDNA fragmentomics (cfFrag) scores were constructed using the optimal three fragmentomics profiles (CNV, FSR, and FSD) to predict breast cancers in the training cohort. A total 132 133 of 24 (3×8) top base learners were selected to create the final cfFrag score by the 5-fold cross-validation AUC in the training cohort (Figures S3 and S4). Among the three feature types, CNV 134 showed the highest mean AUC of 0.742 [0.661 - 0.791] for its top 8 base learners, while the FSD and 135 FSR showed similar predict power in mean AUC (0.706 [0.631 - 0.750]) and 0.706 [0.647 - 0.754]; 136 137 Table S2). The top-performing features for each feature type were identified by summarizing the ranking of their relative importance in each base learner, as shown in Tables S3, S4, and S5, 138 respectively. 139

140 To illustrate the impact of these top-performing features on the final cfFrag model, a recursive

141 feature elimination analysis was performed. We constructed multiple cfFrag models using various subsets of top-performing features and evaluated their performances in the training and validation 142 143 cohorts. The cfFrag model showed possible overfitting in the training cohort by using only subsets of top-performing features in the final model (Figure S5). The 5-fold cross-validation AUCs in the 144 training cohort gradually decreased as more features were used in the model construction process. 145 The fragmentomics model illustrated a solid discriminatory power between the breast cancer and 146 benign nodules, yielding AUCs of 0.82 (95% CI: 0.76 - 0.88) and 0.81 (95% CI: 0.75 - 0.87) in 147 training and external validation cohorts, respectively (Figure 3B). 148

149 The distribution patterns of the cfFrag scores showed significant differences between the benign nodule and breast cancer groups in the training cohort (Wilcoxon, $P = 3.9 \times 10^{-14}$; Figure S6), 150 suggesting the cfFrag scores were positively associated with the probability of breast cancer. A 151 152 similar trend was observed in the prospective validation cohort, with the breast cancer group showing a significantly higher cfFrag score than the benign nodule group ($P = 4.8 \times 10^{-13}$; Figure 3C). It 153 achieved a specificity of 51.5% (95% CI: 38.9-64.0%) at the designed 90% sensitivity (95% CI: 83.3 154 - 94%) in the independent validation cohort, resulting in an overall accuracy of 77.5% (95% CI: 71.2 155 - 83.0%; Table 1). Setting the cut-off value at 85% sensitivity, the fragmentomics model reached 156 specificities of 65.7% (95% CI: 55.6 - 74.8%) and 60.6% (95% CI: 47.8 - 72.4%) in the training and 157 validation cohorts, respectively (Table S6). 158

To verify the specificity of the cfFrag score in healthy women, we analyzed the cfDNA WGS data from 119 asymptomatic healthy women to generate the cfFrag scores. As a result, it yielded an excellent specificity of 94.1% (112/119, 95% CI: 88.3 – 97.6%; Table 1 and Figure 3D) for both cut-off values for 85% and 90% sensitivities.

The cfDNA fragmentomics (cfFrag) model maintains excellent performances in subgroup analysis and correlation with clinical features

To address the potential bias brought by the imbalanced age between breast cancer and benign nodule patients, a propensity score matching analysis was performed. We selected 112 patients (64 breast cancers and 48 benign nodules with matching ages) from the training cohort and 174 patients (117 breast cancers and 57 benign nodules with matching ages) from the prospective validation cohort. As a result, the fragmentomics model showed equally excellent predictive ability for breast cancer in these age-matched subsets, yielding AUCs of 0.82 (95% CI: 0.73 – 0.90) and 0.82 (95% CI: 0.75 – 0.88) in the training and validation cohort, respectively (Figure S7A). Similarly, the predictive

model was able to maintain its predictive ability in a cohort containing small nodules (size \leq 1cm), showing a high AUC of 0.83 (95% CI: 0.72 – 0.95) in the validation cohort (Figure S7B), compared to the traditional imaging methods (AUCs = 0.64 and 0.80 for mammography and ultrasound, respectively; Figure S8).

A subgroup analysis focused on the model's performance was also performed to investigate potential bias. The sensitivities remained high for detecting various breast cancer subgroups, including the nodule size, stages, histology, and hormone receptor (HR) status (Figure S9). As the size of the benign nodules increased, the ability to identify different subgroups with specificity decreased (< 2cm: 54.9%, 2 - 5cm: 40.0%; Figure S10).

In addition to conducting subgroup analysis within the validation cohort, we performed a bootstrap analysis to minimize potential bias. Sensitivities derived from 100 bootstrap iterations for various breast cancer subgroups displayed patterns similar to our previous observations (Figure S11). Additionally, the specificities for the benign nodule subgroup, assessed through 100 bootstrap iterations, align with the trends seen in the validation cohort (Figure S12).

To demonstrate the performance for early detection, the cfFrag scores showed a significant gradual increase from the benign nodule to the DCIS and early-stage (stages I and II) breast cancer (ANOVA, $P = 1.1 \times 10^{-11}$; Figure 3E). Although the cfFrag score distribution showed no significant difference between the HR-positive and HR-negative groups, as well as between the TNBC and non-TNBC groups, the HER2-negative group's cfFrag scores were significantly higher than the HER2-positive group (Wilcoxon, $P = 4.1 \times 10^{-3}$; Figure 3F and Figure S13). This suggested the potential relation between the cfDNA fragmentomics features and the molecular subtypes.

193The cfDNA fragmentomics (cfFrag) model demonstrates robust performance in the194down-sampling process and technical replicates

To decrease the potential cost and required blood samples in the future, we assessed the cfFrag model's performance using downsampled WGS data $(5 - 1 \times)$ in the validation cohort with five technique repeats generated for each coverage depth. The fragmentomics model maintained its predictive power during the down-sampling process without showing a significant decrease in AUCs, even at a depth of $3 \times (P > 0.05;$ Figure 4A).

To assess the robustness of the cfFrag model within and between runs, two batches of 10ml peripheral blood samples were collected from the six patients with a median interval of five days. The plasma samples were separated into three equal proportions as technical replicates for each batch,

resulting in 36 samples. The model extracted and evaluated the fragmentomics profiles of these 36 samples. All three fragmentomics profiles (CNV, FSR, and FSD) showed no significant differences between the technical replicates and the two batches (Figure S14). Additionally, the robustness analysis showed no significant differences between runs and within runs (Wilcoxon, P = 0.2 - 1.0; Figure 4B).

208 The cfDNA fragmentomics (cfFrag) model can also predict the therapeutic pathological response 209 for breast cancer patients after neoadjuvant chemoradiotherapy

To expand the clinical utility of the cfFrag model to predict the treatment response, we applied 210 this assay to 33 female breast cancer patients receiving the NAC. The cfDNA fragmentomics profiles 211 were generated using post-NAC plasma samples and were subsequently predicted by the cfFrag 212 model. As a result, the cfFrag scores for pCR patients were significantly lower than the non-pCR 213 patients (Wilcoxon, $P = 3.6 \times 10^{-3}$; Figure 4C). However, it is noted that the cfFrag scores for the pCR 214 215 patients were still higher than those for patients with benign nodules. Moreover, the cfFrag model demonstrated excellent performance in distinguishing between patients with pCR and with non-pCR, 216 yielding an AUC of 0.82 (95% CI: 0.68 – 0.97; Figure 4D). This indicated that the cfFrag model has 217 218 the potential to predict the therapeutic response and minimal residual disease for post-NAC breast cancer patients. 219

220 The fragmentomics and methylation of cfDNA exhibit complementarity in breast cancer detection

To investigate the potential use of combined WGS with whole-genome bisulfite sequencing 221 222 (WGBS) data for the differentiating power of breast cancers and benign nodules. We selected 39 patients from the prospective validation cohort (including 15 breast cancers and 24 benign nodules) 223 224 enrolled in a methylation-based breast cancer early detection analysis to generate the breast cancer risk score (the cfMeth score) through the WGBS [4]. We found that the cfFrag and cfMeth scores 225 were positively correlated (Spearman's rank correlation coefficient, R = 0.5, $P = 1.2 \times 10^{-3}$; Figure 4E). 226 Due to the limited size, leave-one-out cross-validation was performed. The combined (cfFrag + 227 cfMeth) model showed better performance (AUC=0.96, 95% CI: 0.89 – 1.00) than the cfFrag model 228 alone (AUC=0.88, 95% CI: 0.77 - 0.99) and the cfMeth model alone (AUC=0.86, 95% CI: 0.75 -229 230 0.98), while the addition of imaging data (cfFrag + cfMeth + Xray + Ultrasound) further improved the performance (AUC = 0.97, 95% CI: 0.92 - 1.00; Figure 4F). 231

- 232 The joint diagnostic model combining the cfDNA fragmentomics (cfFrag) scores and breast
- 233 *imaging shows superior performance in detecting breast cancer*

To further improve the performance of the cfDNA fragmentomics-based approach cost-effectively, a joint diagnostic model was constructed by integrating the cfFrag scores and the breast imaging reporting and data system (BI-RADS) categories for mammography and ultrasound using the machine-learning process. As a result, the joint model risk score exhibited a significant difference between the breast cancer and benign nodule groups in both the training and validation cohorts (Wilcoxon, $P < 2.2 \times 10^{-16}$; Figures 5A and 5B).

The joint diagnostic model showed superior performance for distinguishing breast cancers from 240 benign nodules, with AUCs of 0.94 (95% CI: 0.90 - 0.97) and 0.93 (95% CI: 0.89 - 0.97) in the 241 training and validation cohorts, respectively (Figure 5C), which was significantly higher than the 242 cfFrag model alone, as well as the traditional mammography and ultrasound (all P < 0.05; Figure 243 S14). Furthermore, the joint model could reach a high specificity of 80.3% (95% CI: 68.7 – 89.1%) at 244 the designed 90.2% sensitivity (95% CI: 84.1 - 94.5%) in the independent validation cohort (Table 2). 245 Furthermore, the joint model maintained its performance within women with the BI-RADS 4 lesions, 246 reaching AUCs of 0.91 (95% CI: 0.86 - 0.95) and 0.91 (95% CI: 0.86 - 0.96) in the training and 247 validation cohorts, respectively (Figure 5D). 248

The joint model illustrates the potential for increased early detection rates and improved survival outcomes in China and the USA

To assess the potential clinical benefits of the joint model in a real-world setting, we utilized an intercept model developed by Hubbell *et al* [24]. Currently, only 18% of breast cancer patients are diagnosed at stage I in China. By utilization of the joint model, the detection rate of stage-I breast cancer could be elevated to 93%. Accordingly, less breast cancer would be diagnosed at stages II-IV. Based on the stage shifts, it was estimated that the joint model could increase the 5-year survival rates of breast cancer in China by 14% (Figure 5E). Similarly, in the USA, the increased detection rate of stage-I breast cancer (95%) and the 5-year survival benefit (8%) are also estimated (Figure 5F).

258 **Discussion**

259 Current imaging-based breast cancer screening methods suffer from high false positives and inconclusive results among female patients with benign breast nodules, which leads to intrusive 260 biopsy and unnecessarily adds to the discomfort. In our study, we provided a highly sensitive, 261 non-invasive diagnostic tool for early-stage breast cancer detection through the blood-based cfDNA 262 fragmentomics analysis, especially against control with radiographically 263 patients

malignant-suspicious vet pathologically benign breast nodules. Notably, we have demonstrated a 264 significant complementarity between cfDNA fragmentomics, traditional imaging, and cfDNA 265 266 methylation features in the early detection of breast cancer and the assessment of the benign or malignant nature of breast nodules. The combination of cfDNA fragmentomics and traditional 267 imaging findings, as well as the combination of cfDNA fragmentomics and cfDNA methylation 268 features, can further enhance the diagnostic accuracy of breast cancer, aligning with our previous 269 findings on combining cfDNA methylation and traditional imaging in breast cancer. The joint 270 diagnostic model, integrating our non-invasive cfDNA fragmentomics assay with image findings, 271 achieves high diagnostic accuracy (AUCs=0.93 - 0.94). Accordingly, the joint model can guide 272 biopsy decisions and reduce unnecessary invasive interventions by 80.3-85.3% in patients with 273 suspicious imaging results. 274

The detection rate/sensitivity is crucial to avoid cancer diagnostic delay. Thus, 85-90% 275 sensitivities for early-stage breast cancer were set as the primary endpoint for the fragmentomics and 276 joint models in this study. The fragmentomics-only and joint models performed robust detection rates 277 in early-stage breast cancer, even in women with small nodules or inconclusive imaging results 278 279 (BI-RADS 4 lesions). Due to the potential stage shift and increase in the stage-I breast cancer diagnosis rate, our joint model was estimated to save a significant number of breast cancer patients 280 (an extra 8 - 14%) in the USA and China. However, further real-world studies are still needed to 281 identify the cut-off value for each model with the best cost-effectiveness in different populations. 282

283 The detection rates were robustly elevated across increasing breast cancer stages in this study. Intriguingly, the cfDNA fragmentomics signal was more significant in patients with DCIS than those 284 285 with stage-I breast cancer, which is consistent with our methylation-based cfDNA analysis [4] but inconsistent with previous mutation-based cfDNA analysis [25]. It indicates the advantages of 286 287 epigenetic-based and fragmentomics-based cfDNA analysis in the early detection of DCIS/stage-0 breast cancer. In addition, the cfFrag model has shown sufficient specificity in asymptomatic healthy 288 women, further indicating the potential clinical utility of the cfFrag model in population-based breast 289 290 cancer screening.

The use of peripheral cfDNA has gained prominence in early cancer detection, as methylation-based and fragment-based cfDNA markers have demonstrated effectiveness in detecting many cancer types [4, 13-15, 26]. Methylation features in cfDNA are related to the cancer tissue-of-origin, while cfDNA fragmentomics features are linked to the abnormal DNA nuclease

activities in cancers [27]. Compared to the methylation-based cfDNA approach, fragment-based cfDNA assays offer advantages such as lower cost by avoiding sodium bisulfite treatment and requiring less blood sample volume because of low sequence depth. Interestingly, our combined analysis of cfDNA methylation and fragmentomics reveals that combining the fragmentomics (cfFrag score) and the methylation markers (cfMeth score) could achieve superior performance than each marker separately, which was in agreement with the result of the recent sub-study in the Circulating Cell-free Genome Atlas [28].

Monitoring treatment response is crucial to deciding the subsequent treatment strategies for breast cancer patients receiving NAC, but this was unmet using the current methods [29]. Recently, mutation-based and methylation-based ctDNA detection approaches have been demonstrated to predict the treatment response and residual disease in post-NAC breast cancer patients [30, 31]. Our study suggests that the features of cfDNA fragmentomics could be used as an alternative approach to evaluate the treatment response in breast cancer patients.

308 Limitations

Firstly, the sample size of the combining analysis of the cfDNA fragmentomics and methylation 309 is relatively small. Multi-omics cfDNA analysis with large sample sizes is still needed to identify the 310 optimal non-invasive combination with low cost using a trace amount of blood sample for the early 311 312 detection of breast cancer. Secondly, similar to most previous cfDNA fragmentomics studies that only focused on one cancer type [13-15], we also aimed to identify the breast cancer-specific cfDNA 313 314 fragmentomics features in this study. With the identification of the cfDNA fragmentomics spectrum in 315 different cancer types in the future, it would be cost-effective to develop a pan-cancer diagnostic 316 model to detect multiple types of cancer and indicate the cancer origin.

317 Conclusions

This pilot study systematically evaluates performance in applying cfDNA fragmentomics as a non-invasive biomarker for breast cancer. The low-depth cfDNA fragmentomics profiling with automated machine learning demonstrated excellent and robust performance in distinguishing early-stage breast cancers from benign nodules with inconclusive imaging results, the predictive value of NAC response, and sufficient specificity in asymptomatic healthy women in a multi-center prospective setting. The combination of non-invasive cfDNA fragmentomics features and standard

diagnostic imaging improved the rate of accurate detection of early breast cancer. This approach
 holds promise for improving clinical outcomes and streamlining healthcare practices.

326 Materials and methods

327 Study Design and Participants

In this multi-center study, we recruited female patients independently in three centers in China. 328 The training set enrolled 200 consecutive female patients with malignant-suspicious breast imaging 329 results from the YYH in Yantai. The external independent validation sets, referred to as Beijing 330 cohorts, prospectively enrolled 209 consecutive female patients who underwent breast lesion biopsy, 331 33 female breast cancer patients after NAC, and six female patients with repeating samples for 332 robustness analysis from the CHCAMS in Beijing. The external screening cohort recruited 119 333 334 asymptomatic healthy women from our previous Nanjing cohort [14]. The recruitment period was from January 1, 2019, to August 1, 2022. This study adhered to the guidelines of the STARD 335 (Standards for Reporting of Diagnostic Accuracy Studies). 336

337 Sample Collection and Clinical Evaluation

We collected 10 ml of peripheral blood samples from each participant before biopsy or surgery. 338 339 In the Yantai cohort (training set), the collected blood samples were kept in EDTA blood collection tubes (Becton Dickinson, CA) at a temperature of 4°C and underwent centrifugations (1,800 g for 10 340 341 minutes and 16,000 g for 10 minutes both at 4°C) within 2 hours. In the Beijing cohorts (independent validation set), the collected blood samples were kept in the CELL-FREE DNA BCT® blood 342 343 collection tubes (Streck, NE) at room temperature (RT, $15 - 25^{\circ}$ C). Plasma was extracted within 48 344 hours following blood collection by centrifugations of the blood according to the protocols in the 345 training set.

Standard mammography and ultrasonography techniques were conducted at two centers and 346 independently interpreted according to the BI-RADS standard. Patients with suspicious breast 347 imaging results underwent surgical or core needle biopsies. The pathological examination of tissue 348 349 specimens confirmed the malignant or benign status of each participant. Women with negative imaging or biopsy results were excluded from having breast cancer after a 6-month follow-up. The 350 molecular subtype of each lesion was determined according to the pathologic criteria for HR 351 352 (including estrogen receptor and progesterone receptor) and human epidermal growth factor receptor 2 (HER2) [32]. 353

354 Library preparation and whole genome sequencing

For the cfDNA extraction, we used the liquid handling platform (Hamilton Microlab STAR, 355 356 Hamilton Company, NV) and the QIAamp Circulating Nucleic Acid Kit (Qiagen, Germany) according to previously reported protocols [13]. The Qubit dsDNA HS Assay Kit (Thermo Fisher 357 Scientific, MA) was then utilized for measuring the extracted cfDNA's concentration. The PCR-free 358 WGS library was automatically constructed on Biomek (Beckman Coulter, UK), using 5-10 ng of 359 cfDNA sample and the KAPA Hyper Prep Kit (KAPA Biosystems, MA). The constructed library was 360 quantified by the KAPA SYBR FAST qPCR Master Mix (KAPA Biosystems, MA) before paired-end 361 sequencing on NovaSeq platforms (Illumina, CA). 362

For the quality control of bioinformatics analysis, Trimmomatic [33] was used to trim the raw sequencing data. The removal of PCR duplicates was performed by the Picard toolkit (<u>http://broadinstitute.github.io/picard/</u>). The high-quality reads were then mapped to the human reference genome (GRCh37/UCSC hg19) using BWA sequence aligner [34].

367 Fragmentomics profiling

368 As tumor cell fragments are shorter than those from normal cells [35], the FSR profile analyzes 369 the ratio of short fragments in the human genome. Short fragments are defined as 100 - 150 bp and long fragments are defined as 151 – 220bp [13, 15, 20]. The human genomes were divided into 5Mb 370 371 bins, in which the ratios of short to long fragments were calculated, resulting in a total of 1,082 (541 bins \times 2) FSR features. The FSD profile focused on the detailed length patterns of cfDNA fragments, 372 373 categorizing these fragments based on increments of 5bp in the range of 100bp to 220bp [13, 36]. The proportion of fragments in each bin was computed on the human chromosome arm level for human 374 375 autosomes, resulting in 936 FSD features that machine learning algorithms can employ. The CNV profile was calculated using ichorCNA [15]. For each sample, the genome was divided into 1Mb bins. 376 377 The depth for each bin was then compared to the default baseline using the Hidden Markov Model (HMM). The log2 ratio for each bin was calculated, generating 2475 features. The profiling of Griffin, 378 379 neomer, and MBP was present in Supplementary methods (File S1).

380 cfFrag Model construction and validation

A machine-learning process that utilizes five different algorithms, including the random forest, the generalized linear model, the deep learning, the gradient boosting machine, and the eXtreme gradient boosting [13], was employed to generate optimal base learners. A breast cancer prediction model, namely the cfFrag scores, was developed using the mean value of top base learners ranked by

the AUC of the 5-fold cross-validation for the optimal three fragmentomics profiles in the training
cohort (Yantai cohort; File S1).

387 The machine-learning process was also utilized to develop a joint diagnostic model for the training cohort, which adopts the cfFrag scores and the BI-RADS categories of mammography and 388 ultrasound. A similar automated machine-learning process was used to construct the joint diagnostic 389 model by using the cfFrag scores as numeric features and the BI-RADS by mammography and 390 ultrasound as categorical features. The process utilized a randomized search for automatic algorithm 391 selection and hyperparameter tuning. The best-performing model was selected from a total of 200 392 trained models based on the highest AUC using the training cohort via a 5-fold cross-validation 393 approach. Cut-off values were determined using a 5-fold cross-validation to predict the score of the 394 training cohort to reach 85% and 90% sensitivities. The external independent validation cohorts 395 evaluated the joint diagnostic models' performance. In addition, to expand the clinical utility of the 396 397 cfFrag model, its performance was further evaluated in the NAC cohort.

398 Statistical Analysis

The receiver operating characteristic (ROC) curves were generated by the pROC package (version 1.17.0.1) [37]. The sensitivity, specificity, and accuracy with the corresponding 95% confidence intervals (CI) were calculated by the epiR package (version 2.0.19) [38]. Propensity score matching analysis used the MatchIt package (version 4.2.0) [39]. All statistical analyses, including student's *t*-test, Wilcoxon, and ANOVA, were performed in R (version 3.6.3) [40].

404 **Ethical statement**

This study was reviewed and approved by the ethics committees of each center (22/291-3493 for the CHACMS and 2020-289 for the YYH). Each participant provided written informed consent.

407 **Data and code availability**

Raw data from the deidentified participant and analytic code generated in this study are available
for non-commercial use upon reasonable request to Dr. Jiaqi Liu (j.liu@cicams.ac.cn).

410

411 **Competing interests**

412 Drs Tang, Bao, Chang, Zhu, Yang, Xuxiaochen Wu, Xue Wu, and Shao are employees of Nanjing

Geneseeq Technology Inc. All the other authors have no conflict of interest to declare. All the authors have read and approved the final manuscript for publication.

415 Acknowledgments

- 416 This research was funded in part by the National Natural Science Foundation of China (82272938
- 417 to Jiaqi Liu), the Beijing Nova Program (20220484059 to Jiaqi Liu), and the CAMS Innovation
- 418 Fund for Medical Sciences (2021-I2M-1-014 to Jiaqi Liu). This study is part of the DETEct study
- 419 (Deciphering Epigenetic signatures in Tumor and Exploiting ctDNA). We thank all the individuals
- 420 involved in the study for their participation.

421 **References**

- 422 [1] Pace LE, Keating NL. A systematic assessment of benefits and risks to guide breast cancer
 423 screening decisions. JAMA 2014;311:1327-35.
- 424 [2] Giaquinto AN, Sung H, Miller KD, Kramer JL, Newman LA, Minihan A, et al. Breast cancer
 425 statistics, 2022. CA Cancer J Clin 2022;72:524-41.
- [3] Bevers TB, Helvie M, Bonaccio E, Calhoun KE, Daly MB, Farrar WB, et al. Breast cancer
 screening and diagnosis, Version 3.2018, NCCN clinical practice guidelines in oncology. J Natl
 Compr Canc Netw 2018;16:1362-89.
- [4] Liu J, Zhao H, Huang Y, Xu S, Zhou Y, Zhang W, et al. Genome-wide cell-free DNA methylation
 analyses improve accuracy of non-invasive diagnostic imaging for early-stage breast cancer.
 Mol Cancer 2021;20:36.
- [5] Corcoran RB, Chabner BA. Application of cell-free DNA analysis to cancer treatment. N Engl J
 Med 2018;379:1754-65.
- [6] Bidard FC, Hardy-Bessard AC, Dalenc F, Bachelot T, Pierga JY, de la Motte Rouge T, et al.
 Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising
 ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised,
 open-label, multicentre, phase 3 trial. Lancet Oncol 2022;23:1367-77.
- [7] Henry NL, Somerfield MR, Dayao Z, Elias A, Kalinsky K, McShane LM, et al. Biomarkers for
 systemic therapy in metastatic breast cancer: ASCO guideline update. J Clin Oncol
 2022;40:3205-21.
- [8] Liu J, Huang Y, Wang X. Mutation-based circulating tumor DNA detection approach for
 monitoring the therapy response in breast cancer. J Natl Cancer Cent 2023;3(4):254-5.
- [9] Alix-Panabières C, Pantel K. Liquid biopsy: From discovery to clinical application. Cancer
 Discov 2021;11:858-73.
- [10] Cohen JD, Li L, Wang Y, Thoburn C, Afsari B, Danilova L, et al. Detection and localization of
 surgically resectable cancers with a multi-analyte blood test. Science 2018;359:926-30.

- [11] Gianni C, Palleschi M, Merloni F, Di Menna G, Sirico M, Sarti S, et al. Cell-free DNA
 fragmentomics: A promising biomarker for diagnosis, prognosis and prediction of response in
 breast cancer. Int J Mol Sci 2022;23(22):14197.
- [12] Wu SL, Zhang X, Chang M, Huang C, Qian J, Li Q, et al. Genome-wide
 5-hydroxymethylcytosine profiling analysis identifies MAP7D1 as a novel regulator of lymph
 node metastasis in breast cancer. Genomics Proteomics Bioinformatics 2021;19:64–79.
- [13] Bao H, Wang Z, Ma X, Guo W, Zhang X, Tang W, et al. Letter to the Editor: An ultra-sensitive
 assay using cell-free DNA fragmentomics for multi-cancer early detection. Mol Cancer
 2022;21:129.
- [14] Wang S, Meng F, Li M, Bao H, Chen X, Zhu M, et al. Multidimensional cell-free DNA
 fragmentomic assay for detection of early-stage lung cancer. Am J Respir Crit Care Med
 2023;207:1203-13.
- [15] Ma X, Chen Y, Tang W, Bao H, Mo S, Liu R, et al. Multi-dimensional fragmentomic assay for
 ultrasensitive early detection of colorectal advanced adenoma and adenocarcinoma. J Hematol
 Oncol 2021;14:175.
- [16] Moldovan N, van der Pol Y, van den Ende T, Boers D, Verkuijlen S, Creemers A, et al.
 Multi-modal cell-free DNA genomic and fragmentomic patterns enhance cancer survival and
 recurrence analysis. Cell Rep Med 2024;5:101349.
- [17] Liu D, Yehia L, Dhawan A, Ni Y, Eng C. Cell-free DNA fragmentomics and second malignant
 neoplasm risk in patients with PTEN hamartoma tumor syndrome. Cell Rep Med
 2024;5:101384.
- [18] Helzer KT, Sharifi M, Sperger JM, Shi Y, Annala M, Bootsma ML, et al. Fragmentomic analysis
 of circulating tumor DNA targeted cancer panels. Ann Oncol 2023;34(9):813-25.
- [19] Wu N, Zhang Z, Zhou X, Zhao H, Ming Y, Wu X, et al. Mutational landscape and genetic
 signatures of cell-free DNA in tumour-induced osteomalacia. J Cell Mol Med 2020;24:4931-43.
- [20] Cristiano S, Leal A, Phallen J, Fiksel J, Adleff V, Bruhm DC, et al. Genome-wide cell-free DNA
 fragmentation in patients with cancer. Nature 2019;570:385-9.
- [21] Georgakopoulos-Soares I, Barnea OY, Mouratidis I, Bradley R, Easterlin R, Chan C, et al.
 Leveraging sequences missing from the human genome to diagnose cancer. medRxiv
 2021:2021.08.15.21261805.
- [22] Doebley AL, Ko M, Liao H, Cruikshank AE, Santos K, Kikawa C, et al. A framework for clinical
 cancer subtyping from nucleosome profiling of cell-free DNA. Nat Commun 2022;13:7475.
- [23] Guo W, Chen X, Liu R, Liang N, Ma Q, Bao H, et al. Sensitive detection of stage I lung
 adenocarcinoma using plasma cell-free DNA breakpoint motif profiling. EBioMedicine
 2022;81:104131.
- [24] Hubbell E, Clarke CA, Aravanis AM, Berg CD. Modeled reductions in late-stage cancer with a
 multi-cancer early detection test. Cancer Epidemiol Biomarkers Prev 2021;30:460-8.
- [25] Chin YM, Takahashi Y, Chan HT, Otaki M, Fujishima M, Shibayama T, et al. Ultradeep targeted
 sequencing of circulating tumor DNA in plasma of early and advanced breast cancer. Cancer
 Sci 2021;112:454-64.

- [26] Xu RH, Wei W, Krawczyk M, Wang W, Luo H, Flagg K, et al. Circulating tumour DNA
 methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nat Mater
 2017;16:1155-61.
- [27] Zhou Z, Ma ML, Chan RWY, Lam WKJ, Peng W, Gai W, et al. Fragmentation landscape of
 cell-free DNA revealed by deconvolutional analysis of end motifs. Proc Natl Acad Sci U S A
 2023;120:e2220982120.
- [28] Jamshidi A, Liu MC, Klein EA, Venn O, Hubbell E, Beausang JF, et al. Evaluation of cell-free
 DNA approaches for multi-cancer early detection. Cancer Cell 2022;40:1537-49.e12.
- [29] Graeser M, Schrading S, Gluz O, Strobel K, Würstlein R, Kümmel S, et al. Early response by
 MR imaging and ultrasound as predictor of pathologic complete response to 12-week
 neoadjuvant therapy for different early breast cancer subtypes: Combined analysis from the
 WSG ADAPT subtrials. Int J Cancer 2021;148:2614-27.
- [30] Magbanua MJM, Brown Swigart L, Ahmed Z, Sayaman RW, Renner D, Kalashnikova E, et al.
 Clinical significance and biology of circulating tumor DNA in high-risk early-stage
 HER2-negative breast cancer receiving neoadjuvant chemotherapy. Cancer Cell
 2023;41:1091-102.e4.
- [31] Moss J, Zick A, Grinshpun A, Carmon E, Maoz M, Ochana BL, et al. Circulating breast-derived
 DNA allows universal detection and monitoring of localized breast cancer. Ann Oncol
 2020;31:395-403.
- 506 [32] Waks AG, Winer EP. Breast cancer treatment: A review. JAMA 2019;321:288-300.
- [33] Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data.
 Bioinformatics 2014;30:2114-20.
- [34] Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform.
 Bioinformatics 2009;25:1754-60.
- [35] Jiang P, Chan CW, Chan KC, Cheng SH, Wong J, Wong VW, et al. Lengthening and shortening
 of plasma DNA in hepatocellular carcinoma patients. Proc Natl Acad Sci U S A
 2015;112:E1317-25.
- [36] Zhang X, Wang Z, Tang W, Wang X, Liu R, Bao H, et al. Ultrasensitive and affordable assay for
 early detection of primary liver cancer using plasma cell-free DNA fragmentomics. Hepatology
 2022;76(2):317-329.
- [37] Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, et al. pROC: an open-source
 package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 2011;12:77.
- [38] Stevenson M, Nunes T, Sanchez J, Thornton R, Reiczigel J, Robison-Cox J, et al. EpiR: An R
 package for the analysis of epidemiological data. 2013; 9–43. Available online: https://cran.r-universe.dev/epiR (accessed on 1 Oct 2022).
- [39] Ho D, Imai K, King G, Stuart EA. MatchIt: Nonparametric preprocessing for parametric causal
 inference. J Stat Softw. 2011;42:1-28.
- [40] R Core Team. R: A Language and Environment for Statistical Computing. 2021. Available online: https://www.R-project.org/ (accessed on 1 Oct 2022).
- 526

527

528

529 Figure legends



531 **Figure 1. Study Design.**

530

Plasma samples collected from patients with breast cancers or benign nodules were used to extract cfDNA. WGS was performed on the cfDNA to generate fragmentomics feature types. The fragmentomics machine learning model was constructed using the optimal three fragmentomics profiles in the training set, including FSR, FSD, and CNV. Five different algorithms were utilized in the automatic machine-learning process. For each feature type, the top three models with the

highest AUCs of 5-fold cross-validation in the training cohort were selected, and the mean cancer
score (the cfFrag score) was used for the fragmentomics model. The cfFrag model was developed in
the training cohort and evaluated in the validation cohorts. Abbreviation: cfDNA, cell-free DNA;
WGS, whole-genome sequencing; FSR, fragment size ratio; FSD, fragment size distribution; CNV,
copy number variation; GLM, generalized linear model; GBM, gradient boosting machine; RF,
random forest; DL, deep learning; XGBoost, eXtreme gradient boosting; AUC, area under the
curve; CV, cross-validation.

544



546

547 Figure 2. Patient Enrollment.

In this multi-center study, we recruited 200 consecutive female patients with malignant-suspicious 548 breast imaging results from the Yantai cohort as the training set. As a result, 91 patients with breast 549 cancer and 102 women with benign breast nodules were enrolled, and seven patients who refused to 550 biopsy were excluded. The external validation cohorts were composed of a screening cohort of 551 healthy women in Nanjing (N = 119) and three independent validation cohorts in Beijing, namely 552 the prospective validation cohort (N = 209), the neoadjuvant chemotherapy validation cohort (N =553 33), and the robustness analysis cohort (N = 6). *The prospective validation cohort included 39 554 participants (14 with breast cancer and 25 with benign nodules) enrolled in a methylation-based 555 early detection analysis for breast cancer through whole-genome bisulfite sequencing [4]. 556 Abbreviation: NAC, neoadjuvant chemotherapy; pCR, pathological complete response. 557



559 Figure 3. Evaluation of the cfDNA Fragmentomics (cfFrag) Model.

560 A. Boxplots for AUCs of top base learners for six different cfDNA fragmentomics features. The t-test P values are 0.0011, 0.0043, 0.027, 0.17, 0.34, and 0.086 for these features, respectively. **B**. 561 562 ROC curves using the training cohort (5-fold cross-validation) and the independent validation cohort. C. Violin plot illustrating cfFrag score distribution in the independent validation cohort's 563 benign nodule and breast cancer groups. The cutoffs, shown as the dotted lines, were determined by 564 the training cohort. **D.** Violin plot using cfFrag cancer risk scores in 119 healthy female volunteers 565 from our previous study [13]. The cfFrag scores for most healthy women (112/119) were lower than 566 both cut-off values, yielding an excellent specificity of 94.1%. E. The box plot illustrating cfFrag 567 score distribution in the benign nodule group and very early (DCIS), and early-stage (stages I and II) 568 breast cancer groups. F. The box plot illustrating the cfFrag score distribution of different subgroups 569 in the validation cohort. Abbreviation: CNV, copy number variation. FSD, fragment size 570 distribution. FSR, fragment size ratio. MBP, motif breakpoint; AUC, area under the curve; CV, 571 cross-validation; ns, not significant; sens, sensitivity; BN, benign nodule; ROC, receiver operating 572 characteristic; DCIS, ductal carcinoma in situ; HR, hormone receptor; HER2, human epidermal 573 574 growth factor receptor 2.



576 Figure 4. Comprehensively Evaluating cfFrag Model Using Additional Cohorts.

577 **A.** Box plot for the validation cohorts' AUCs for the down-sampling process ($5 \times to 1 \times$). There is no significant performance drop till $3 \times$ coverage (ns, no significance; ** P < 0.01). **B.** Box plot for 578 579 cfFrag scores in external test cohort containing 3 breast cancer patients and 3 benign nodule patients. For each patient, two batches × three repeats were performed. C. ROC curve for 580 distinguishing patients with pathological complete response (N = 9) from patients without 581 pathological complete response (N = 24) in a neoadjuvant therapy cohort. **D.** Violin plot using 582 cfFrag cancer risk scores in patients with pCR and non-pCR. E. Scatter plot showing the correlation 583 between cfMeth scores and cfFrag scores for a subset of patients in the validation cohort (N = 39) 584 with previously reported whole-genome bisulfite sequencing data [4]. F. ROC curves for a subset of 585 patients in the validation cohort (N = 39) with previously reported whole-genome bisulfite 586 sequencing data [4] and imaging data using leave-one-out cross-validation. BC, breast cancer; BN, 587 benign nodule; sens, sensitivity; NAC, neoadjuvant chemotherapy; pCR, pathological complete 588 response; AUC, area under the curve. 589



Figure 5. Evaluating Performance for Joint Model Using Both Fragmentomics and Imaging Techniques.

A. Violin plots illustrating cancer score distribution of the joint model in the benign nodule and 593 breast cancer groups in the training cohort. B. The score distribution of the joint model in the 594 benign nodule and breast cancer groups in the independent validation cohort. C. ROC curves using 595 596 the training cohort (5-fold cross-validation) and the independent validation cohort. D. ROC curves for subset patients with BI-RADS category 4 in the training cohort (5-fold cross-validation) and the 597 598 validation cohort. E. Potential clinical benefit evaluation using breast cancer statistics in China. F. Potential clinical benefit of the joint model in the USA. The left bars show the current stage 599 600 distributions of newly diagnosed breast cancer, and the middle bars indicate the stage distributions for potential clinical utilization of the joint model in the two countries. Accordingly, mortality shifts 601 602 and 5-year survival benefits (orange bars) achieved by using the joint model are shown in the right bars. Abbreviation: sens, sensitivity; BI-RADS, breast imaging reporting and data system. 603

604

	Training cohort (5-fold cross-validation)	Prospective validation cohort	Asymptomatic healthy women
Breast cancer patients (n)	91	143	-
Benign nodule patients (n)	102	66	-
Healthy controls (n)	-	-	119
Sensitivity (95% CI)	90.1% (82.1-95.4%)	89.5% (83.3-94%)	-
Specificity (95% CI)	52.0% (41.8-62.0%)	51.5% (38.9-64%)	94.1% (88.3-97.6%)
PPV (95% CI)	62.6% (53.7-70.9%)	80.0% (73.0-85.9%)	-
NPV (95% CI)	85.5% (74.2-93.1%)	69.4% (54.6-81.7%)	-
Accuracy (95% CI)	69.9% (62.9-76.3%)	77.5% (71.2-83%)	-

605 Table 1. Evaluating the cfFrag Model Performances in the Training and Validation Cohorts.

Abbreviation: CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value.

Table 2. Evaluating the Joint Model Performances in the Training and Validation Cohorts.

	Training cohort (5-fold cross-validation)	Prospective validation cohort
Breast cancer patients (n)	91	143
Benign nodule patients (n)	102	66

Sensitivity (95% CI)	90.1% (82.1-95.4%)	90.2% (84.1-94.5%)
Specificity (95% CI)	85.3% (76.9-91.5%)	80.3% (68.7-89.1%)
PPV (95% CI)	84.5% (75.8-91.1%)	90.8% (84.9-95.0%)
NPV (95% CI)	90.6% (82.9-95.6%)	79.1% (67.4-88.1%)
Accuracy (95% CI)	87.6% (82.1-91.9%)	87.1% (81.8-91.3%)

609 Abbreviation: CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value.

610

611

612 Supplemental material

613 File S1. Supplementary methods

614

Figure S1. Multi-omic Cell-free DNA Profiles of Breast Cancer Patients, and Subjects with Benign Nodule.

A. Frequencies of chromosome arm-level copy number variations (CNVs) in subjects with breast cancers and benign nodules. Amplifications are represented in red, while losses are depicted in blue.
B. Fragment size distribution (FSD) in chromosome 18p across various groups. The distribution illustrates the fragment size profiles among subjects with benign nodules and breast cancers. C. Ratio of short (100-150bp) fragments to long (150-220bp) fragments across all 5Mb bins on chromosomal arms in subjects with breast cancers and benign nodules. Abbreviation: CNV, copy number variation; BC, breast cancer; BN, benign nodule.

Figure S2. The ichorCNA Tumor Fraction Distribution of Breast Cancer and Benign Nodule in the Training Cohort and the Validation Cohort.

We used the ichorCNA reported tumor fraction (TF) to show the differences in CNV profile between breast cancer (BC) patients and benign nodule (BN) patients. The TF by ichorCNA was significantly higher for the BC patients compared to the BN patients in both the training cohort ($P = 8 \times 10^{-5}$) and the validation cohort (P = 0.029). This suggests that while the BC and BN groups both vary substantially from health baselines, there are still distinguishable differences between the two groups. Abbreviation: TF, tumor fraction; CNV, copy number variation; BC, breast cancer; BN, benign nodule.

633 Figure S3. The Area Under the Curve Distribution of Base Learners in the Training Cohort.

A total of 24 (3×8) top base learners were selected to create the final cfFrag score by the 5-fold

635 cross-validation AUC in the training cohort. Abbreviation: AUC, area under the curve.

636 Figure S4. ROC Curves for Selected Base Learners in the Training Cohort.

- Among the three feature types, CNV showed the highest mean AUC of 0.742 [0.661 0.791] for its
- top 8 base learners, while the FSD and FSR showed similar predict power in mean AUC (0.706
- 639 [0.631-0.750] and 0.706 [0.647-0.754]), as shown in Table S3. Abbreviation: CNV, copy number
- 640 variation; AUC, area under the curve; FSD, fragment size distribution; FSR, fragment size ratio.
- 641 Figure S5. Feature Recursive Feature Elimination Analysis in the Training Cohort and the
- 642 Validation Cohort.

The cfFrag model showed possible overfitting in the training cohort using only subsets of top-performing features in the final model. The 5-fold cross-validation AUCs in the training cohort showed a gradual decrease as more features were used in the model construction process. Abbreviation: AUC, area under the curve.

647 Figure S6. The cfFrag Score Distribution in the Training Cohort (5-fold cross-validation).

Figure S7. ROC Curve of the cfFrag Model in Subsets of Age-matched Patients and Patients with Small Nodule (≤1cm) in the Training and Validation Cohorts.

650 A. Receiver operating characteristic (ROC) curves of the cfFrag model using an age-matched subset

651 in the training cohort (5-fold cross-validation) and the independent validation cohort. **B.** ROC curves

of the cfFrag model using an age-matched subset in the training cohort (5-fold cross-validation) and

653 the independent validation cohort. The shadow areas indicate the 95% confidence intervals (CI).

- 654 Abbreviation: ROC, receiver operating characteristic; AUC, area under the curve; CI, confidence 655 interval.
- **Figure S8. ROC Curves for Traditional Imaging Technique in Different Cohorts.**
- Abbreviation: BI-RADS, Breast Imaging Reporting and Data System; ROC, receiver operating
 characteristic; AUC, area under the curve.
- 659 Figure S9. Performance Evaluation for Fragmentomics Model in Different Subgroups of Breast
- 660 **Cancer Patients in the Validation Cohort.**
- 661 Abbreviation: HR, hormone receptor; HER2, human epidermal growth factor receptor 2; TNBC,
- triple-negative breast cancer; BI-RADS, Breast Imaging Reporting and Data System.
- 663 Figure S10. Performance Evaluation for Fragmentomics Model in Different Subgroups of
- 664 **Patients with Benign Nodule in the Validation Cohort.**
- 665 Abbreviation: BI-RADS, Breast Imaging Reporting and Data System.

666 Figure S11. Bootstrapped (100 times) Performance Evaluation of Fragmentomics Model in

- 667 Breast Cancer Subgroups in the Validation Cohort.
- 668 The sensitivities derived from 100 bootstrap iterations for various breast cancer subgroups displayed
- patterns similar to our observations in Figure S5. Abbreviation: HR, hormone receptor; HER2, human
 epidermal growth factor receptor 2; TNBC, triple-negative breast cancer.
- 671 Figure S12. Bootstrapped (100 times) Performance Evaluation of Fragmentomics Model in
- 672 Benign Nodule Subgroups in the Validation Cohort.
- 673 The specificities for the BN subgroup, assessed through 100 bootstrap iterations, align with the trends

- 674 seen in the validation cohort (Figure S6).
- 675 Figure S13. The cfFrag Score Distribution of Different Subgroups in the Validation Cohort (HR,
- 676 **HER2, and TNBC).**
- 677 Abbreviation: NS, no significance; HR, hormone receptor; HER2, human epidermal growth factor
- 678 receptor 2; TNBC, triple-negative breast cancer.
- 679 Figure S14. The Feature Correlation of Inter- and Intra-run Samples.
- 680 No significant differences were observed between the technical replicates and the two batches in all
- three fragmentomics profiles, including copy number variation (A), fragment size distribution (B),
- and fragment size ratio (C). Abbreviation: CNV, copy number variation; FSD, fragment size
- 683 distribution; FSR, fragment size ratio.
- Figure S15. Comparing the Joint Model against the Fragmentomics Model, Mammography,
 and Ultrasound.
- 686 ROC curves for the training cohort (A; 5-fold cross-validation) and the prospective validation cohort
- (B). The Wilcoxon *P* values compare the joint model against each individual technique. Abbreviation:
 AUC, area under the curve.
- 689
- 690 Table S1. Patient Characteristics.
- **Table S2. Selected top-performing base learners for constructing the final cfFrag model.**
- 692 Table S3. CNV features ranked by their importance.
- 693 Table S4. FSR features ranked by their importance.
- 694 **Table S5. FSD features ranked by their importance.**
- **Table S6. Evaluating the Fragmentomics Model Performances at 85% Sensitivity Cutoff.**